Tryptamine Therapeutics Limited
TYPTF
$0.015
-$0.0001-0.66%
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
There are no news to display.
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, February 26, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
End of April (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
61 3 9092 0475
Address
697 Burke Road
Camberwell, VIC 3124
Camberwell, VIC 3124
Country
Year Founded
Business Description
Sector
Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the...
more
